Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867529 · ClinicalTrials.gov registry record · Phase 2
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
A Phase 2 study of Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue and Nodal Marginal Zone B-cell Lymphoma, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT00867529 is a Phase 2 study of Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue and Nodal Marginal Zone B-cell Lymphoma that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 63 participants, above the 49-participant average among 11 other Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00867529, a Phase 2 study of Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue and Nodal Marginal Zone B-cell Lymphoma, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of improvement (relapsed). Monoclonal antibodies, such as rituximab, can interfere with the ability of cancer cells to grow and spread. Giving rituximab before and after a donor peripheral blood stem cell transplant may help stop cancer from coming back and may help keep the patient's immune system from rejecting the donor's stem cells.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL rituximab
- OTHER pharmacological study
- PROCEDURE peripheral blood stem cell transplantation
- PROCEDURE nonmyeloablative allogeneic hematopoietic stem cell transplantation
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00867529
The ClinicalTrials.gov registry entry for NCT00867529 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 49-participant average among 11 other Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue trials with a reported enrollment target (29% higher). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00867529 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00867529 about?
NCT00867529 is a clinical study titled "Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma". This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of improvement (relapsed). Monoclonal antibodies, such as rituximab, can interf...
What is the current status of trial NCT00867529?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2009-02. Estimated completion is 2015-03-26.
What conditions does trial NCT00867529 study?
This clinical trial studies the following conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Intraocular Lymphoma.
What interventions are being tested in trial NCT00867529?
The interventions under investigation include: laboratory biomarker analysis (OTHER), rituximab (BIOLOGICAL), pharmacological study (OTHER), peripheral blood stem cell transplantation (PROCEDURE), nonmyeloablative allogeneic hematopoietic stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00867529?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00867529 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
COMPLETED · Phase 2
-
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
COMPLETED · Phase 2
-
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
COMPLETED · Phase 2
-
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
COMPLETED · Phase 2
-
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
All registered trials for this condition
Nodal Marginal Zone B-cell Lymphoma
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.